| Literature DB >> 35145828 |
Shreya Reddy1, Hetal Brahmbhatt2.
Abstract
Batten disease is a rare group of neurological diseases, specifically called neuronal ceroid lipofuscinosis. This is a genetic disorder and usually manifests during childhood. Batten disease is fatal and there is currently no proven cure. However, there are certain treatment methods that show potential in mitigating the aftermath of the disease. This review will explore the application and effectiveness of antiepileptic drugs, anticonvulsants, and vitamin C in multiple scenarios to treat Batten disease. Anticonvulsants are a broad group of medications that are used to treat epileptic seizures. Epileptic seizures are a big indicator of Batten disease, making anticonvulsants a potential treatment for Batten disease patients. Antiepileptic drugs also work to stop seizures by decreasing neurological excitation, thus for the same reason are often grouped alongside anticonvulsants and are being investigated as a promising way to help Batten disease patients. Vitamin C helps maintain the integrity of several intracellular processes in the central nervous system, which makes it a possible candidate for treating Batten disease. The known effects of anticonvulsants, antiepileptic drugs, and vitamin C on Batten disease are very limited and should be considered more often by healthcare professionals because of their potential effects on patients with Batten disease.Entities:
Keywords: anticonvulsant; antiepileptic drug; batten disease; seizures; vitamin c
Year: 2022 PMID: 35145828 PMCID: PMC8803372 DOI: 10.7759/cureus.21745
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Summary of previous research of the manipulation of anticonvulsants, antiepileptic drugs, and vitamin C in the comprehension and care of Batten disease
N/A: not applicable; HCl: hydrochloric acid; siRNA: small interfering ribonucleic acid; CLN3: ceroid lipofuscinosis, neuronal type 3
| Author (Year) and Sample Size | Treatment Type and Dosage | Results |
| Aberg et al. (1997), 16 [ | Anticonvulsant (lamotrigine), 0.5 milligram/kilogram of body weight for 15 patients, one patient had their dose increased over two weeks to 4.7 milligrams/kilogram of body weight | Lamotrigine had a favorable effect in nearly all of the patients over two years |
| Aberg et al. (1999), 28 [ | Anticonvulsant (lamotrigine), started at 0.1-0.5 milligram/kilogram of bodyweight per day, then increased every two weeks up to 1.25-15 milligram/kilogram of body weight per day | Lamotrigine had a good effect in 23/28 patients |
| Clausen et al. (1988), 73 [ | Anticonvulsant sodium selenite and vitamin C; Sodium selenite: 94.5 microgram/kilogram of body weight per day, Vitamin C: 14.3 milligram/kilogram of body weight per day | Lower selenium levels in patients were found to correlate to neurological issues similar to Batten disease By taking vitamin C and sodium selenite daily, some abnormalities of Batten disease were reduced in all patients |
| Santavuori et al. (1988), 74 [ | Vitamin C 0.008-0.025 milligrams/kilogram of body weight per day | Decreased menstruation periods in women, which correlated with a decrease in seizures |
| Santavuori et al. (2009), 125 [ | Vitamin C 0.008-0.025 milligrams/kilogram of body weight per day | No progress or only slight progress was observed in mental/neurological symptoms of Batten disease |
| Sass et al. (1999), 2 [ | Vitamin C (naturally made by the body of the patients); concentration: 103.6-148.7 micromoles/liter | Vitamin C levels are decreased in some patients who have neurological disorders like Batten disease |
| Aberg et al. (2000), 60 [ | Anticonvulsants valproate, lamotrigine, phenobarbital, felbamate; valproate: 10 milligram/kilogram of body weight per day, lamotrigine: 0.5 milligram/kilogram of body weight per day, phenobarbital: 1 milligram/kilogram of body weight per day, felbamate: 5-10 milligram/kilogram of body weight per day | An overall decrease in 50% of the seizures was observed |
| Boustany (1992), 80 [ | Anticonvulsants clonazepam and valproic acid; dosages are N/A | N/A |
| Conry (2002), N/A [ | Anticonvulsants valproic acid, ethosuximide, lamotrigine, benzodiazepines, piracetam, zonisamide; zonisamide: 100-600 milligrams daily for two-three years | Zonisamide shows promise in treating epilepsies, valproic acid is effective but should be used with caution in young children |
| Georgiou et al. (2020), 1 [ | Anticonvulsants levetiracetam (1000 milligrams twice a day), sodium valproate (400 milligrams twice a day), lamotrigine (125 milligrams twice a day), zonisamide (100 milligrams in the morning, 150 milligrams at night), diazepam (10 milligrams, given when required) | For three months after treatment, the patient did not experience major seizure activity of sporadic jerks in the palms |
| Kohlschütter et al. (1993), 11 [ | Anticonvulsants barbiturates and valproate; dosages: N/A | Barbiturates caused erythrocyte ethanolamine phosphoglycerides and phosphatidylethanolamine plasmalogens to decrease; Valproate treatment had no effect on erythrocyte ethanolamine phosphoglycerides and phosphatidylethanolamine plasmalogen levels |
| Larsen and Ostergaard (2014), 35 [ | Anticonvulsant valproate 60-1000 milligrams daily | Valproate had a variety of effects, the most common being: valproate-induced hyperammonemic encephalopathy, drowsiness, and decreased seizures |
| Johannsen et al. (2016), 2 [ | Anticonvulsant valproate at 63-75 milligrams/liter | On the patient who received the lower dose, there were only mild and intermittent effects on the Batten disease onset; On the other patient, there was only a mild reduction of symptoms |
| Kohlschütter et al. (1988), 17 [ | Anticonvulsant; specific drug and dosage: N/A | Anticonvulsants caused increased fluidity in the membrane when membrane fluidity in juvenile Batten disease patients tends to be less |
| Patel (2008), 1 [ | Anticonvulsant valproic acid 15 milligrams/kilograms of body weight per day | Report of breakthrough seizure activity especially in mornings |
| Kohlschütter (1988), 29 [ | Anticonvulsant; specific drug and dosage: N/A | Concluded that anticonvulsants should be used judiciously |
| Yamaguchi et al. (2020), 35 [ | Anticonvulsant; specific drug and dosage: N/A | A true relationship between anticonvulsant and Batten disease could not be established |
| Maertens et al. (1995), 7 [ | Anticonvulsant phenytoin; dosage: N/A | Phenytoin doesn’t cause a statistical difference in the activity of free radical metabolism of patients of Batten disease |
| An Haack et al. (2011), N/A [ | Antiepileptic drugs amiodarone, cis diltiazem HCl, felodipine, flavoxate HCl, isradipine | All show significant lowering in calcium levels in CLN3 siRNA knockdown cells, which reduces defects in the CLN3 cells, leading to less presence of Batten disease |